Grossmann KF, Othus M, Patel SP, et al. Adjuvant pembrolizumab versus IFNα2b or ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12(3):644–53. https://doi.org/10.1158/2159-8290.CD-21-1141.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkin J, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023. https://doi.org/10.1158/1078-0432.CCR-22-3145.

Article  PubMed  PubMed Central  Google Scholar 

Eggermont AMM, Kicinski M, Blank CU, et al. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022. https://doi.org/10.1056/EVIDoa2200214.

Article  PubMed  Google Scholar 

Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139–48. https://doi.org/10.1056/NEJMoa2005493.

Article  CAS  PubMed  Google Scholar 

Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399(10336):1718–29. https://doi.org/10.1016/S0140-6736(22)00562-1.

Article  CAS  PubMed  Google Scholar 

Kirkwood JM, Del Vecchio M, Weber J, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023. https://doi.org/10.1038/s41591-023-02583-2.

Article  PubMed  PubMed Central  Google Scholar 

Patel SP, Othus M, Chen Y, et al. Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813–23. https://doi.org/10.1056/NEJMoa2211437.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Ferris L, Faries MB, Luke JJ. Debating sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. J Clin Oncol. 2023;41(26):4204–7. https://doi.org/10.1200/JCO.23.00255.

Augustin RC, Luke JJ. Progression/recurrence-free survival 2 in adjuvant melanoma. N Engl J Med Evid. 2022. https://doi.org/10.1056/EVIDe2200240.

Article  Google Scholar 

Augustin RC, Luke JJ. PD-1 Monotherapy reigns supreme in adjuvant melanoma…but for how long? Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29(17):3253–5. https://doi.org/10.1158/1078-0432.CCR-23-1194.

Article  CAS  Google Scholar 

Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660–70. https://doi.org/10.1038/s41590-022-01141-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results the EORTC 18071 double-blind phase 3 randomized trial. J Clin Oncol. 2019;37(15_suppl):2512. https://doi.org/10.1200/JCO.2019.37.15_suppl.2512.

Article  Google Scholar 

Luke JJ, Ascierto PA, Khattak MA, et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. J Clin Oncol. 2023;41(17):LBA9505. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA9505.

Article  Google Scholar 

Livingstone E, Zimmer L, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. Lancet Lond Engl. 2022;400(10358):1117–29. https://doi.org/10.1016/S0140-6736(22)01654-3.

Article  CAS  Google Scholar 

Khushalani NI, Vassallo M, Goldberg JD, et al. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022;10(11): e005684. https://doi.org/10.1136/jitc-2022-005684.

Article  PubMed  PubMed Central  Google Scholar 

Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023;41(3):517–27. https://doi.org/10.1200/JCO.22.00533.

Article  CAS  PubMed  Google Scholar 

Augustin RC, Luke JJ. Induction exposure dose of ipilimumab and failure of adjuvant nivolumab plus ipilimumab in melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(3):443–6. https://doi.org/10.1200/JCO.22.01770.

Article  CAS  Google Scholar 

Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105–10. https://doi.org/10.1245/s10434-018-6513-7.

Article  PubMed  Google Scholar 

Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92. https://doi.org/10.3322/caac.21409.

Article  PubMed  PubMed Central  Google Scholar 

Garbe C, Keim U, Amaral T, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(32):3741–9. https://doi.org/10.1200/JCO.22.00202.

Article  CAS  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15_suppl):9506. https://doi.org/10.1200/JCO.2021.39.15_suppl.9506.

Article  Google Scholar 

Swetter SM, Thompson JA, Albertini MR, et al. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2021;19(4):364–76. https://doi.org/10.6004/jnccn.2021.0018.

Article  PubMed  Google Scholar 

Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–609. https://doi.org/10.1056/NEJMoa1310460.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol. 2020;27(1):15–21. https://doi.org/10.1245/s10434-019-07830-w.

Article  PubMed  Google Scholar 

Long GV, Kirkwood JMM, Hoeller C, et al. Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K). J Clin Oncol. 2023;41(16_suppl):9504. https://doi.org/10.1200/JCO.2023.41.16_suppl.9504.

Article  Google Scholar 

Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491–500. https://doi.org/10.1245/ASO.2006.05.013.

Article  PubMed  Google Scholar 

Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178–88. https://doi.org/10.1038/s41591-022-01851-x.

Article  CAS  PubMed  Google Scholar 

Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411):eaar3593. https://doi.org/10.1126/science.aar3593.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui C, Xu C, Yang W, et al. Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021;6(1):1–12. https://doi.org/10.1038/s41525-021-00169-w.

Article  CAS  Google Scholar 

Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8(1):49. https://doi.org/10.1186/s40364-020-00228-x.

Article  PubMed  PubMed Central  Google Scholar 

Gocher AM, Workman CJ, Vignali DAA. Interferon-γ: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158–72. https://doi.org/10.1038/s41577-021-00566-3.

Article  CAS  PubMed  Google Scholar 

Damotte D, Warren S, Arrondeau J, et al. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort. J Transl Med. 2019;17(1):357. https://doi.org/10.1186/s12967-019-2100-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930–40. https://doi.org/10.1172/JCI91190.

Article  PubMed  PubMed Central  Google Scholar 

Spranger S, Luke JJ, Bao R, et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci USA. 2016;113(48):E7759–68. https://doi.org/10.1073/pnas.1609376113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bao R, Stapor D, Luke JJ. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types. Genome Med. 2020;12(1):90. https://doi.org/10.1186/s13073-020-00787-6.

Article  CAS  PubMed